The Effect of Sacubitril / Valsartan on Diastolic function of HFmrEF patients by Tissue Doppler

Document Type : Original Article

Authors

1 Cardiology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt

2 Cardiology, Cardiology, Health Insurance Organization, Cairo, Egypt

10.21608/aimj.2025.446602

Abstract

Background: The left ventricular ejection fraction (EF) plays a critical role in diagnosing heart failure, determining its characteristics, predicting its outcome, and making decisions about treatment.
Aim of the work: To examine the impact of Sacubitril / Valsartan on the diastolic function of patients with heart failure and mildly reduced ejection fraction (HFmrEF).
Patients and methods: An interventional study targeting patients with HFmrEF for 90 days of follow-up after initiating Sacubitril/Valsartan as part of their standard care was conducted at Suez Health Insurance Cardiology Clinic and Helwan Insurance Hospital.
Results: 94 patients (62% males; 60.9 ± 8.84 years) with HFmrEF in NYHA class II–IV were evaluated. A significant improvement in the NYHA class and diastolic function after treatment with standard doses (P<0.001). 63% of the patients had diastolic dysfunction grade 3, and 2% had better grades after 3 months of S–V treatment. Moreover, there was a reduction in E/e′ ratio from (11.8) to (9.9) with non-significant changes in systolic function.
Conclusion: In addition to an improvement in NYHA class and symptoms in patients with HFmrEF Sacubitril/Valsartan significantly improved diastolic parameters, This echocardiographic improvement is particularly relevant in those patients with better NYHA class at 3-month follow-up.

Keywords

Files

Share

How to cite

Statistics